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Abstract
Background: Direct hemoperfusion with polymyxin B-immobilized fiber column (PMX-DHP) could improve the
hemodynamic status of septic shock patients. As PMX-DHP is an invasive and costly procedure, it is desirable to
estimate the therapeutic effect before performing the therapy. However, it is still unclear when this therapy should
be started and what type of sepsis it should be employed for. In this study, we retrospectively examined the clinical
effect of patients treated with PMX-DHP by using central venous pressure (CVP).
Methods: Seventy patients who received PMX-DHP for septic shock during the study period were recruited and
divided into a low CVP group (n = 33, CVP < 12 mmHg) and a high CVP group (n = 37, CVP≧12 mmHg). The primary
endpoint was vasopressor dependency index at 24 hours after starting PMX-DHP, and the secondary endpoint was
the 28-day survival rate. Additionally, we performed a multivariate linear regression analysis on the difference in the
vasopressor dependency index.
Results: The vasopressor dependency index significantly improved at 24 h in the low CVP group (0.33 to 0.16 mmHg−1;
p < 0.01) but not in the high CVP group (0.43 to 0.34 mmHg−1; p = 0.41), and there was a significant difference between
the two groups in the index at 24 h (p = 0.02). The 28-day survival rate was higher in the low CVP group (79 vs. 43 %; p <
0.01). Multivariate linear regression analysis showed that CVP (p= 0.04) was independently associated with the difference
in the vasopressor dependency index.
Conclusions: Our study indicates that the clinical effect of PMX-DHP for septic shock patients with higher CVP
(≧12 mmHg) might be limited and that the initial CVP when performing PMX-DHP could function as an independent
prognostic marker for the hemodynamic improvement.
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Background
Both the 2008 and 2012 Surviving Sepsis Campaign
Guidelines (SSCG) recommend the rapid infusion of
intravenous fluids until a central venous pressure (CVP)
of 8–12 mmHg is achieved during initial resuscitation
[1, 2]. However, many studies show that excess fluid
accumulation is associated with adverse outcomes in
critically ill patients [3–5]. In particular, positive fluid
balance seems to be harmful for patients whose comor-
bid burden includes chronic heart failure and/or chronic
kidney disease [6, 7]. In order to avoid excess volume
expansion in those patients, it is important to carefully
monitor intravascular volume by the following parame-
ters: CVP, stroke volume variance, or extravascular lung
water.
Direct hemoperfusion with a polymyxin B-immobilized
fiber column (PMX-DHP), which can effectively adsorb
bacterial endotoxin and lead to an earlier recovery from
shock state, was first reported in 1994, and it has been
used for the treatment of septic shock in many countries
[8–11]. Although many clinical reports, including two
randomized control trials, have shown the clinical effect
of adapting PMX-DHP for septic shock patients, there is
no clear consensus about the effect of the hemoperfusion
[9–12]. As PMX-DHP is an invasive and costly procedure,
it is desirable to accurately estimate the therapeutic effect
before performing the therapy [11]. However, it is still
unclear when this therapy should be started and what type
of sepsis it should be employed for.
The utility of CVP as a marker of intravascular volume
has been questioned for many years [13, 14]. However,
we consider that CVP is one of the most widely used
hemodynamic parameters because of the promptness of
the measurement and the ability to perform it in any
hospital facility. Actually, many clinical studies also dem-
onstrated that high CVP was associated with positive
fluid balance [1, 5, 15].
In this study, in order to clarify the application of
PMX-DHP for septic shock patients, we retrospectively
examined the hemodynamic improvement and the mor-
tality of patients treated with PMX-DHP by using CVP
values. Moreover, we investigated whether the CVP
values at the start of PMX-DHP could function as an
independent prognostic factor for the hemodynamic
improvement of the hemoperfusion.
Methods
Patients
We conducted a retrospective cohort study among all
consecutive patients who received PMX-DHP for septic
shock between May 2008 and April 2013 in the intensive
care unit (ICU), high care unit (HCU), and cardiovascu-
lar care unit (CCU) at the Japanese Red Cross Kyoto
Daini Hospital and the Kyoto University Hospital in
Japan. After initial resuscitation to achieve the early goal
directed therapy (EGDT), PMX-DHP was applied along
the Japanese health insurance system, as follows [1]: septic
shock patients who require vasopressor support because
of endotoxin or gram-negative bacteria. The following
patients were excluded: (1) those who were under 18 years
old, (2) those who were admitted to the ICU, HCU, or
CCU for reasons other than sepsis, (3) those who were
not given vasopressors when starting PMX-DHP, and (4)
those in whose medical records CVP was not sufficiently
recorded.
The Ethics Committee of Kyoto University Graduate
School and Faculty of Medicine approved the protocol
(E2153). This study was retrospective and used only a
data bank while employing the highest privacy policy
standards. Therefore, the requirement of informed
consent was waived.
Procedures
Vascular access was placed at the femoral or the
internal jugular vein. PMX-DHP with PMX-20R (Toray
Industries, Tokyo, Japan) was performed for at least
120 min per session once or twice per patient per day
for 2 days. The blood flow volume was 80–120 mL/min.
The duration of hemoperfusion was decided by the
attending physician. The therapy was terminated when
the attending physician deemed it appropriate to conclude
PMX-DHP for any reason. The anticoagulant used in
PMX-DHP was nafamostat mesilate, low molecular weight
heparin, or unfractionated heparin. All other cardiovascu-
lar management, including cardiac output management,
setting of blood pressure goals, and fluid and inotropic
therapy, were performed on the basis of SSCG recommen-
dations by the attending physician.
Definitions and classification
In this study, we classified the patients into two groups:
patients with CVP values greater than or equal to (≧)
12 mmHg when starting PMX-DHP were placed in the
high CVP group, while the remaining patients whose
CVP values were less than (<) 12 mmHg were placed in
the low CVP group. CVP was measured using the stand-
ard method when starting PMX-DHP and expressed as
mmHg, as described previously [16, 17]. This classifica-
tion is also based on the SSCG recommendations, which
suggest that in mechanical ventilation patients, a higher
target CVP of 12 mmHg should be achieved [2].
Data collection
We employed three parameters in order to compare
hemodynamic status among the patients in this study:
mean arterial pressure (MAP), inotropic score, and
vasopressor dependency index, as described in the
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preceding studies [9, 18]. Namely, the inotropic score
was calculated as follows:
ðdopamine dose μg=kg=min½ Þ
 1 þ dobutamine μg=kg=min½ ð Þ
 1 þ epinephrine dose μg=kg=min½ ð Þ
 100 þ norepinephrine dose μg=kg=min½ ð Þ
 100 þ phenylephrine dose μg=kg=min½ ð Þ  100
And, vasopressor dependency index was calculated as
the inotropic score/MAP. The parameters were calcu-
lated before the first PMX-DHP, immediately thereafter
and 24 h after the first PMX-DHP.
Relevant clinical background, medical history, and
clinical data of all patients were collected at appropriate
times during the treatment for sepsis. Basic cardiopul-
monary data and laboratory data obtained at the time of
starting PMX-DHP were considered baseline values.
These included age, sex, body mass index, systolic blood
pressure, diastolic blood pressure, dopamine infusion rate,
noradrenaline infusion rate, inotropic score, vasopressor
dependency index, heart rate, central venous pressure, car-
diac output, cardiac index, body temperature, arterial pH,
lactate, arterial oxygen tension (PaO2)/fractional inspired
oxygen (FiO2) ratio (P/F ratio), positive end-expiratory
pressure (PEEP), renal replacement therapy, surgery,
hemoglobin, platelet count, C-reactive protein (CRP), total
bilirubin, total protein, Acute Physiologic and Chronic
Health Evaluation II (APACHE II) score, Sequential Organ
Failure Assessment (SOFA) score, time from admission to
care units until starting PMX-DHP, duration of PMX-
DHP, total fluid dosage from ICU admission until starting
PMX-DHP, site of infection, and microorganism types.
Cardiac output and cardiac index were measured by an
arterial catheter attached to the FlotracTM pulse counter
device (VigileoTM, Edwards Lifesciences, Irvine, CA, USA)
or a pulmonary artery catheter attached to VigilanceTM
monitor (VigileoTM, Edwards Lifesciences, Irvine, CA,
USA).
Study outcomes
The primary outcome was vasopressor dependency
index at 24 h after starting PMX-DHP. The secondary
outcome was the 28-day survival rate.
Statistical analysis
Statistical analysis was performed using JMP for Macintosh
version 10.0.2 software (SAS Institute, Tokyo, Japan). Cat-
egorical variables are expressed as the number of patients
(%) and were analyzed by using the χ2 test or Fisher’s exact
test. Continuous variables are expressed as means and 95 %
confidence intervals (CIs). Comparison of continuous vari-
ables between the two groups was conducted with the t test
or the Mann-Whitney U test, according to the distribution
of the variables. Evaluation of significance between groups
over time points was done by repeated measure ANOVA.
As post hoc analysis, the three pair-wise comparisons of
the hemodynamic status within a single group among dif-
ferent time points were made using Bonferroni adjustment.
Therefore, p values less than 0.016 were considered signifi-
cant only in this comparison. In the other comparisons,
statistical significance was defined as p values <0.05.
Kaplan-Meier curves were constructed for the comparison
of the survival rate in the two groups and were tested for
difference using the log-rank test.
To ensure the assumption that the CVP at the begin-
ning of PMX-DHP could be an independently prognostic
factor for the hemodynamic improvement of the hemo-
perfusion, we performed a multivariate linear regression
analysis that focused on the difference in the vasopressor
dependency index before PMX-DHP and 24 h after
hemoperfusion. The relationships between the parameter
and continuous variables were examined using Pearson’s
correlation coefficient, and categorical variables were
examined using Spearman’s R test. All variables with
p values <0.20 in the univariate analysis were in-
cluded in the multivariate analysis. To ensure that the
assumptions for regression analysis were not violated,
an analysis of residuals was carried out. Moreover, we
performed multivariate Cox regression analysis to




Although 112 patients received PMX-DHP for septic
shock during the study period, 70 patients met the
inclusion criteria, while 42 patients were excluded for
a variety of reasons (age, 2; reasons for admission to
ICU, 13; vasopressors not used, 9; no record of CVP,
18). Of these 70 patients, the initial CVP of 33
patients when receiving PMX-DHP was <12 mmHg,
and the initial CVP of the other 37 patients was
≧12 mmHg, as shown in Fig. 1. The baseline charac-
teristics of the study population are described in
Table 1. Although the SOFA score, in particular
SOFA liver and SOFA hematological, was significantly
higher in the high CVP group than in the low CVP
group, the APACHE II score was not significantly
different between the two groups. Arterial pH was
also significantly lower in the high CVP group. There
were no significant differences in the other parame-
ters except CVP. Although cardiac pump dysfunction
could have a serious influence on CVP value, there
was not a significant difference between the two
groups in cardiac output and cardiac index before
starting PMX-DHP.
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Table 2 shows the site of infection and microorganism
types in both groups. There were also no significant
differences between them.
Primary outcome
Repeated measures ANOVA for the vasopressor depend-
ency index revealed that the index in the low CVP group
improved more significantly than in the high CVP group
(for each p < 0.01) (Fig. 2). As for post hoc analysis, the
vasopressor dependency index decreased significantly at
24 h (0.16 mmHg−1; 95 % CI, 0.05–0.28; p < 0.01) but
not after PMX-DHP (0.24 mmHg−1; 95 % CI, 0.15–0.34;
p = 0.14) in the low CVP group whereas the decrease
was observed neither after PMX-DHP (0.39 mmHg−1;
95 % CI, 0.30–0.49; p = 1.00) nor at 24 h (0.34 mmHg−1;
95 % CI, 0.25–0.44; p = 0.41) in the high CVP group.
Additionally, we could observe a significant difference in
the index at 24 h between the two groups (p < 0.05)
(Fig. 3). Thus, PMX-DHP appeared to be more effective
for the hemodynamic status in the low CVP group than
in the high CVP group.
Secondary outcome
The survival rates of both groups after 28 days were ana-
lyzed by the Kaplan-Meier method (Fig. 3). The survival
rate was significantly higher in the low CVP group than
in the high CVP group (p < 0.01), as determined by log-
rank test.
Regression analysis
Correlation analyses were performed to identify factors
associated with the difference in the vasopressor
dependency index before and 24 h after PMX-DHP
(Additional file 1: Table S1). In the univariate regression
analysis, age statistically significantly correlated with the
difference (p = 0.03). Subsequent multivariate linear
regression confirmed CVP (p = 0.04) and age (p =
0.03) as independent prognosis factors regarding the
hemodynamic improvement of PMX-DHP (Table 3).
This also indicates that the higher the CVP at the
start of hemoperfusion is, the less it improves the
hemodynamic state.
Discussion
In this study, we observed the association between CVP
and the hemodynamic improvement with PMX-DHP.
Our results yielded two interesting findings. First, the
hemodynamic status of patients with higher CVP did
not improve significantly by PMX-DHP. In other words,
our retrospective results did not support the guideline’s
recommendations, which suggested that septic shock pa-
tients with mechanical ventilation should achieve a
higher target of CVP 12 to 15 mmHg2. Second, the ini-
tial CVP when performing PMX-DHP could function as
an independent prognostic factor for the hemodynamic
improvement of the therapy. To the best of our know-
ledge, this is the first study that investigated this particu-
lar association and prognosis.
Although CVP is one of the most popular hemodynamic
parameters, we cannot deny that CVP values may not re-
flect intravascular volume accurately. In fact, recent re-
views reported that the CVP value is mainly determined
by two factors: cardiac pump function and venous return
function [17, 19, 20]. In terms of cardiac function, a high
CVP indicates a decrease in contractility, diastolic dys-
function, valvular disease, and cardiomyopathy in these
patients, although in our study, there was not a significant
difference in cardiac output and cardiac index [19, 20].
On the other hand, venous return is determined by the
gradient between CVP and the mean circulatory filling
pressure (MCFP), as shown in the formula below:
venous return ¼ MCFP − CVPð Þ=venous resistance
[19] MCFP is the pressure in the vasculature when the
heart is stopped (zero flow) and the pressures in all seg-
ments of the circulatory system have equalized [21, 22].
Thus, an increase in CVP values leads to the decrease
in venous return [19–22]. Because PMX-DHP does
not directly affect these pressures and cardiac func-
tion, it is difficult for the hemoperfusion to improve
the hemodynamic status for septic shock patients with
high CVP.
Actually, in this study, we observed that the patients in
the high CVP group suffered from hemodynamic impair-
ment due to high CVP. The proportion of patients who
received renal replacement therapy was non-significantly
larger in the high CVP group, which suggests that many
Fig. 1 Patient flow diagram for this study. Among 112 patients who
received PMX-DHP for septic shock, 70 patients met the requirements
of our study but 42 patients were excluded for several reasons
as follows: age, 2; reasons for admission to ICU, 13; vasopressors
not used, 9; no record of CVP, 18. The 70 patients were the
divided into two groups: low central venous pressure (CVP)
(CVP <12 mmHg; n = 33) and high CVP (CVP ≧12 mmHg; n = 37)
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of the attending physicians might think the intravascular
volume in the high CVP group patients is too large.
Additionally, the P/F ratio and PEEP were also non-
significantly lower in the high CVP group, which indicated
that some of the patients had a high intrathoracic pres-
sure. Hence, we consider that high CVP group patients
did not have adequate venous return because excess fluid
therapy or high intrathoracic pressure reduces the
Table 1 Baseline characteristics of the patients
Low CVP group n = 33 High CVP group n = 37 p value
Median (95 % CI) Median (95 % CI)
Age, year 72 (68–76) 67 (64–71) 0.07
Male, n(%) 20 (61) 26 (70) 0.46
Body mass index, kg/m2 22 (20–23) 23 (21–24) 0.37
Systolic blood pressure, mmHg 99 (90–106) 92 (84–99) 0.22
Diastolic blood pressure, mmHg 50 (47–53) 48 (44–51) 0.30
Mean blood pressure, mmHg 66 (62–70) 62 (59–66) 0.17
Dopamine infusion rate, μg/kg/min 5.0 (3.5–6.6) 5.8 (4.4–7.3) 0.45
Noradrenaline infusion rate, μg/kg/min 0.12 (0.09–0.16) 0.16 (0.12–0.20) 0.20
Inotropic score 20 (15–25) 25 (21–30) 0.14
Vasopressor dependency index, mmHg−1 0.33 (0.23–0.45) 0.43 (0.34–0.53) 0.15
Heart rate, bpm 109 (103–116) 115 (109–121) 0.18
CVP, mmHg 8 (7–9) 15(14–16) <0.01
Cardiac output, L/min 4.6 (3.3–5.8) 5.7 (4.6–5.7) 0.18
Cardiac index, L/min/m2 2.8 (2.3–3.4) 3.3 (2.8–3.7) 0.23
Body temperture, °C 36.8 (36.4–37.2) 36.8 (36.4–37.2) 0.92
Arterial pH 7.36 (7.32–7.41) 7.27 (7.23–7.31) <0.01
Lactate, mmol/L 3.9 (2.6–5.3) 4.0 (2.9–5.2) 0.94
P/F ratio 220 (181–258) 168 (131–206) 0.06
PEEP, cmH2O 8 (6–10) 9 (7–11) 0.32
Renal replacement therapy, n(%) 13 (39) 23 (62) 0.06
Surgery, n(%) 21 (64) 17 (46) 0.16
Hemoglobin, g/dL 10.4 (9.7–11.1) 10.3 (9.6–11.0) 0.78
Platelet count, ×109/L 111 (87–134) 81 (59–104) 0.08
CRP, mg/dL 17.7 (11.4–24.0) 17.6 (11.6–23.5) 0.97
Total Bilirubin, mg/dL 1.7 (0.2–3.1) 3.6 (2.2–5.0) 0.06
Total Protein, mg/dL 4.9 (4.5–5.3) 4.6 (4.2–4.9) 0.17
APACHE II score 26 (25–28) 28 (26–30) 0.23
SOFA score 12 (11–13) 14 (13–15) 0.01
SOFA cardiovascular 3.5 (3.3–3.7) 3.7 (3.5–3.9) 0.29
SOFA renal 1.9 (1.4–2.4) 2.3 (1.8–2.8) 0.22
SOFA hematological 1.6 (1.2–2.0) 2.1 (1.8–2.5) 0.05
SOFA respiratory 2.4 (1.9–2.8) 2.8 (2.4–3.2) 0.15
SOFA liver 0.8 (0.4–1.2) 1.4 (1.0–1.7) 0.04
SOFA central nerve system 2.0 (1.6–2.5) 2.0 (1.5–2.4) 0.83
Time from ICU admission until starting PMX-DHP, min 441 (98–802) 829 (498–1159) 0.11
PMX-DHP duration, min 354 (249–458) 366 (263–469) 0.97
Total fluid dosage from ICU admission until starting PMX-DHP, ml 2970 (1200–4760) 3212 (1223–5203) 0.86
APACHE Acute Physiologic and Chronic Health Evaluation, CRP c-reactive protein, CVP central venous pressure, ICU intensive care unit, PEEP positive end-expiratory
pressure, P/F ratio arterial oxygen tension/fractional inspired oxygen ratio PMX-DHP direct hemoperfusion with polymyxin B-immobilized fiber column, SOFA
Sequential Organ Failure Assessment
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gradient between MCFP and CVP. On the other hand, the
significant improvement in the low CVP group could be
because they genuinely received the clinical effect of
PMX-DHP. Generally, PMX-DHP can reduce plasma
cytokine levels by absorbing endotoxin, immune cells, and
anandamide [23–25]. These physiological and pathological
responses could be equivalent in both groups in our study.
However, the harmful effect of high CVP at the start of
PMX-DHP differentiated the clinical effect of both groups.
In other words, fluid toxicity or increase in intrathoracic
pressure might be deleterious beyond the beneficial effect
of PMX-DHP in patients with high CVP in our study.
Previous studies have reported that early initiation
of PMX-DHP reduced the catecholamine requirement
and that early improvement in inotropic score and
vasopressor dependency index after PMX-DHP might
be a prognostic factor [18, 23, 26]. In our study, the
patients in the low CVP group who received PMX-
DHP earlier also tended to show a decrease in their
vasopressor dependency index. Meanwhile, in terms
of the time between ICU admission and starting
PMX-DHP, there was neither a statistical difference
between the two groups nor a significant association
with hemodynamic improvement in our study. How-
ever, because the sample size of our study was not large
enough to demonstrate the association, our results should
be viewed with this limitation in mind. In addition,
although we performed PMX-DHP for around 6 h in both
groups, a recent study has indicated that a longer duration
of PMX-DHP therapy can be expected to improve the
hemodynamics and pulmonary oxygenation capacity of
patients with severe sepsis/septic shock [27]. Thus, longer
operation of PMX-DHP might contribute to improve the
outcome of patients with low CVP.
Other limitations of our study need to be acknowledged.
First, we could not show the data on intrinsic PEEP, so-








Urinary tract 7 2
Skin 2 1
Blood stream 0 1
Others 5 5
Microorganism type
Escherichia coli 7 5
Staphylococcus species 2 5
Streptococcus species 1 4
Enterococcus species 1 2
Pseudomonas species 1 2
Bacteroides species 1 1
Klebsiella species 2 0
Serratia species 1 1
Acinetobacter species 1 0
Citrobacter species 0 1
Clostridium species 1 0
Morallexa species 0 1
Stenotrophomonas species 0 1
Fig. 2 Changes in vasopressor dependency index. Each box plot
indicates medians, 25th and 75th percentiles, and whisker caps
indicate 5th and 95th percentiles. White box plots indicate the low
CVP group, and the diagonal-lined box indicates the high CVP group.
An asterisk indicates a significant difference with p < 0.01, and a
dagger indicates a significant difference with p < 0.05. There was a
significant difference between the two groups in the repeated
measure ANOVA. The vasopressor dependency index also
significantly improved at 24 h in the low CVP group (0.28 to
0.16 mmHg−1; p < 0.01) but not in the high CVP group (0.43 to
0.34 mmHg−1; p = 0.10). Additionally, there was a significant
difference in the index at 24 h between the two groups (p < 0.05)
Fig. 3 Survival rate of each group by Kaplan-Meier analysis.
Although patients in both groups were similarly treated with
PMX-DHP, patients in the low CVP group showed a better survival rate
in this study
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called auto-PEEP, which might have a direct influence on
the CVP values in the high CVP group. However, we con-
sider that it may not fundamentally change our conclu-
sion. Auto-PEEP-induced hypotension is not a result of
hyper-inflammatory response to sepsis, but it is rather a
patient-ventilator interaction. Thus, it is obvious that
PMX-DHP is less effective for the high CVP patients with
auto-PEEP-induced hypotension. Additionally, this clinical
study is not for acute exacerbation of chronic obstructive
pulmonary disease, bronchial asthma, or acute respiratory
distress syndrome, and it only evaluated patients with
septic shock. Thus, we consider that there were not a large
proportion of the study patients with auto-PEEP in our
study. Second, the previous studies reported that high
CVP was associated with a poor prognosis [28, 29]. In-
deed, high CVP might have a negative influence on the
cardiac function during the treatment in patients with
high CVP group, although cardiac output and index were
not significantly different in both groups at the beginning
of the hemoperfusion [29]. Therefore, regardless of the
effect of PMX-DHP, there may be a possibility of observ-
ing the clinical course of patients with a poor prognosis.
Third, this study was not a randomized controlled trial,
and we cannot rule out the possibility of selection bias,
especially referral bias and Neyman bias. Fourth, perhaps
we could not extract the patients whose conditions chan-
ged rapidly or whose case was extremely severe because
our study patients had enough time to receive the hemo-
perfusion. Fifth, vasopressors were regulated by local phy-
sicians, depending on the patient’s condition. Therefore,
the protocol for titrating the vasopressors was different
among the attending physicians. Further study is required
to clarify these unsolved issues.
Conclusions
Our study indicated that the effect of PMX-DHP for
septic shock patients with higher CVP (≧12 mmHg)
may be limited and that the initial CVP in performing
PMX-DHP could be an independent prognostic
marker for hemodynamic improvement. Further study
is required to clarify the mechanisms of PMX-DHP
that affect sepsis treatment.
Additional file
Additional file 1: Table S1. Results of univariate regression analysis for
the difference in the vasopressor dependency index between before and
24 h after PMX-DHP. (XLSX 12 kb)
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